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Abstract. Emerging data suggest that nutritional status and
body weight are related to reproductive function, and nutrient
imbalances during pregnancy lead to changes in the expression
of fetal genes. Recent studies show that the mTOR acts as a
placental growth signalling sensor and its expression is down-
regulated in intrauterine growth restriction. To date, very little
is known about the expression of this signalling pathway in
choriocarcinoma, one of the most lethal germ cell cancers. In
this study, cultures of fusigenic (BeWo) and non-fusigenic
(JEG-3) human choriocarcinoma cell lines were used to
investigate the expression of mTOR and its downstream
signalling components. The effects of an inducer of syncytia-
lisation (forskolin) on mTOR, eIF4E binding proteins
(4EBPs) and ribosomal protein S6 kinases (S6Ks) in BeWo
cells were also assessed. RT-PCR studies revealed that
mTOR, 4EBP and S6Ks are expressed at mRNA level in both
JEG-3 and BeWo cells. Semi-quantitative RT-PCR analysis
revealed that in early stages of syncytialisation (50 μM
forskolin for 48 h), the expression of mTOR and 4EBP was
down-regulated when compared to unstimulated cells. In
fully syncytialised cells (50 μM forskolin for 72 h) the
expression of both genes was similar to basal levels.
Interestingly, the phosphorylation (Ser371, Thr389) status of
p70S6K remained unaltered upon forskolin treatment. These
data validate BeWo cells as an experimental model to study
the effects of forskolin-induced syncytialisation on mTOR
signalling. 
Introduction
mTOR functions by integrating extracellular signals (growth
factors and steroid hormones) with amino acid availability
and intracellular energy status to control translation rates and
additional metabolic processes (1). mTOR enhances translation
initiation, in part by phosphorylating two major targets that
cooperate to regulate translation initiation rates, the eIF4E
binding proteins (4EBPs) and the ribosomal protein S6 kinases
(S6K1 and 2) (2). It is now believed that mTOR also functions
as a ‘molecular switch’ through S6 kinase depending on the
status of the cell (3).
There are two isoforms of S6 kinase, S6K· and ß (or S6K1
and 2), which have cytoplasmic (S6K·II and S6KßII) and
nuclear (S6K·I and S6KßI) variants derived from alternative
splicing at the N-terminus. S6K· and ß have a high level of
sequence similarity, with the greatest homology in the kinase
and kinase extension domains; however, they differ significantly
at their N- and C-terminal regulatory regions, sharing only 28
and 25% homology respectively (4). In spite of their apparent
cellular localisation, it is becoming clearer that the regulation
of S6K is more complex. All isoforms are involved in nuclear-
cytoplasmic shuttling which is regulated by their phosphorylation
status resulting in the presence of activated S6K in different
cellular localisations (5-6).
To date, few studies implicated mTOR in placental
signalling. For example, in vitro outgrowth experiments showed
that mTOR deficient blastocysts were severely impaired in their
ability to form trophoblasts (7). mTOR expression is down-
regulated in restricted fetal growth (8), and also functions as
a placental growth signalling sensor (9). Experiments using
immortalised human trophoblast cells revealed that cell pro-
liferation was induced in response to glucose or following
activation of Tie-2 receptor, involving an mTOR signalling
pathway (9). This is of increasing importance since nutrient
imbalances during pregnancy may lead to changes in both
reproductive function (10) and the expression of fetal genes
(11).
Currently, and despite the implications of mTOR signalling
on cancer, there is no data about the involvement of this
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  25:  65-69,  2010 65
Expression of mTOR and downstream signalling 
components in the JEG-3 and BeWo human 
placental choriocarcinoma cell lines 
DIONISIS MPARMPAKAS1,  ELENA ZACHARIADES1,  HELEN FOSTER1,  ANJELI KARA1,
AMANDA HARVEY1,  ANASTASIA GOUMENOU1,2* and EMMANOUIL KARTERIS1*
1Centre for Cell Chromosome Biology, Biosciences, School of Health Sciences and Social Care, 
Brunel University, Uxbridge UB8 3PH, UK; 2University of Crete, Division of Medicine, 
Department of Obstetrics and Gynecology, Heraklion, Crete, Greece
Received February 27, 2009;  Accepted April 7, 2009
DOI: 10.3892/ijmm_00000314
_________________________________________
Correspondence to: Dr Emmanouil Karteris, Centre for Cell
Chromosome Biology, Biosciences, School of Health Sciences and
Social Care, Brunel University, Uxbridge UB8 3PH, UK
E-mail: emmanouil.karteris@brunel.ac.uk
*Contributed equally
Key words: placenta, syncytialisation, mTOR, S6 Kinase, eIF4E
binding proteins
65-69.qxd  13/11/2009  10:06 Ì  Page 65
pathway on gestational trophoblastic diseases (GTD). These
diseases have key characteristics, the abnormal growth of
chorionic tissues and differential expression of oncogenes and
growth factors (12). GTDs are a diverse group of diseases
including complete hydatidiform and invasive moles and
choriocarcinoma and placental site trophoblastic tumours (13).
Interestingly, choriocarcinoma resembles the complete mole,
based on the expression of various oncogenes and growth
factors (12).
In this study we tested the hypothesis that an inducer of
syncytialisation affects the expression of mTOR signalling
components. The specific objectives of this study were: a)
assessment of the expression of mTOR, 4EBPs and the
ribosomal protein S6Ks in two human placental chorio-
carcinoma cell lines (BeWo and JEG-3), b) investigation of
the effects of inducer of syncytialisation (forskolin) on these
genes in BeWo cells.
Materials and methods
Placental tissue. Labouring placental tissues were obtained
from women delivering at term without any complications
(>37 weeks of gestation, n=3). After delivery, the maternal and
fetal surfaces of the placenta were dissected, and fetal mem-
branes were peeled away from the placenta. Placental samples
were washed in PBS and immediately stored in RNALater at
-80˚C. Ethical approval was granted from the local ethics
authority. 
Cell culture. BeWo and JEG-3 cell lines were purchased
from the European Collection of Cell Cultures (ECACC,
Salisbury, UK). The cells were maintained at standard culture
conditions of 5% CO2 in air at 37˚C. BeWo cells were cultured
in Ham F12 (Sigma, UK) containing 10% heat-inactivated
fetal bovine serum (FBS), and 0.5% penicillin-streptomycin,
whereas JEG-3 cells were maintained in MEME (Sigma)
containing 10% heat-inactivated FBS, and 0.5% penicillin-
streptomycin, 0.5% L-glutamine, 0.5% sodium pyruvate and
0.5% MEM non-essential amino acids.
Syncytialisation of BeWo cells. Forskolin (Sigma, UK) was
used as an inducer of syncytialisation in BeWo cytotrophoblast
cells. Syncytialisation of BeWo cells was assessed with 50
and 100 μM forskolin over a total period of 72 h, renewing
forskolin treatment every 24 h. 
RNA isolation, cDNA synthesis and PCR. Total ribonucleic acid
was isolated using an RNA extraction kit (Sigma), according to
manufacturer's instructions. RNA concentration was determined
by spectrophotometric analysis (NanoDrop; Thermo Scientific,
UK) and agarose gel electrophoresis. RNA (500 ng) was
reverse-transcribed into cDNA using 5 IU/μl RNase H reverse
transcriptase (Invitrogen, Paisley, UK). PCR amplification
was performed using Taq polymerase (Invitrogen) and oligo-
nucleotide primers as previously described (14). Twenty-eight
cycles were performed consisting of an initial denaturing step
at 94˚C for 30 sec, annealing at 60˚C for 1 min and elongation
at 72˚C for 1 min. 
Immunofluorescent analysis. BeWo (treated and untreated) and
JEG-3 cells were fixed in 4% paraformaldehyde for 10 min
prior to washes in PBS and incubation with 10% bovine serum
albumin (BSA) for 1 h. Cells were incubated for 1 h with an
mTOR antibody (Santa Cruz Biotechnology, USA) at a 1:100
dilution in 1% BSA/PBS. Cells were then washed with PBS
prior to an incubation with anti-rabbit IgG-fluorescein isothio-
cyanate (FITC)-conjugated antibody (Santa Cruz Biotechnology)
for 1 h. Slides were washed with PBS and mounted in
Vectashield® Mounting Medium (Vector labs) containing the
dye 4,6-diamido-2-phenylindole (DAPI) to counterstain nuclei.
Images were captured using a Plan Apo Neofluor 63X NA
1.25 oil objective (Zeiss) on a Zeiss Axiovert 200 M micro-
scope and viewed using AxioVision software. Images were
taken with a particular exposure time.  
Protein extraction from BeWo cells. BeWo cells were cultured
to 80% confluency, and in the presence or absence of forskolin
(50-100 μM up to 72 h). Cells were then lysed using 200 μl
1X Laemmli buffer (Sigma) and denatured for 5 min at
100˚C before cooled on ice. 
Western immunoblotting. Samples were separated on an SDS-
10% polyacrylamide gel and the proteins were transferred to a
nitrocellulose membrane. The membrane was blocked in TBS
containing 5% dried milk powder (w/v) and 0.1% Tween-20,
for 1 h at room temperature. After three washes with TBS-0.1%
Tween, the nitrocellulose membranes were incubated with
primary antibodies against proliferating cell nuclear antigen
(PCNA), pan-Cadherin, phosphorylated (serine/threonine)
p70S6K, and GAPDH (Cell Signalling, Sigma). The primary
antiserum was used at a 1:1000 dilution overnight at 4˚C. The
membranes were then washed thoroughly for 30 min with
TBS-0.1% Tween, before incubation with the secondary anti-
rabbit HRP-conjugated immunoglobulin (1:2000) for 1 h at
room temperature and further washing for 30 min with
TBS-0.1% Tween. Antibody complexes were visualised as
previously described (15).
The nitrocellulose membranes were then stripped, prior to
incubation with GAPDH antibody. Briefly, pre-warmed
stripping solution (ß-mercaptoethanol 100 mM, 10% SDS,
Tris HCl 62.5 mM) was applied to each membrane and
incubated at 50˚C for 15 min. Fresh stripping solution was
then added to each membrane and incubated at 50˚C for 15 min.
The membranes were briefly washed with dH2O and then
thoroughly washed with TBS-0.1% Tween to ensure complete
removal of ß-mercaptoethanol from membranes before
blocking solution and primary antibody were applied.
Results
Expression of mTOR signalling components. RT-PCR analysis
revealed that BeWo and JEG-3 cells express mTOR, 4EBP and
the S6 kinase isoforms ·1, ·2, ß1 and ß2 at mRNA level. PCR
analyses for the above genes produced PCR products of 537 bp
for mTOR, 299 bp for 4EBP, and 585 bp, 480 bp, 468 bp,
336 bp for the ·1, ·2, ß1 and ß2 S6K isoforms (Fig. 1A). These
PCR products are consistent with those described previously
(14). Immunofluorescent analysis using a specific antibody for
mTOR revealed cytoplasmic localisation of mTOR in both cell
lines (Fig. 1B). The staining of mTOR appeared granular and
dispersed in nature.
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Syncytialisation of BeWo cells. In this experimental model,
syncytialisation was achieved using forskolin. The syncytialisation
model on BeWo cells was evaluated in detail, prior to
elucidating the expression of mTOR signalling components
in the differentiated state (syncytiotrophoblasts) of BeWo cells.
BeWo cells treated with forskolin (50 and 100 μM) for 48 h
revealed down-regulation of expression of PCNA at the mRNA
level (Fig. 2A). At the protein level, the results of Western
blotting demonstrated that after 72 h of exposure to either 50 or
100 μM forskolin PCNA levels were down-regulated compared
to controls (Fig. 2B). These data suggest that BeWo cells
cease to proliferate, indicative of differentiation events taking
place. Analysis of the cell membrane marker cadherin, was
carried out to determine whether there was a decrease of the
total plasma membrane in response to forskolin treatment.
Decrease in plasma membrane levels is indicative of differentiation
as cells become multinucleated during syncytialisation.
Western blotting revealed down-regulation of cadherin protein
levels in BeWo cells treated with forskolin for 72 h at both
50 and 100 μM when compared with controls (Fig. 2B). Equal
protein loading was ensured by stripping and blotting the nitro-
cellulose membranes with an antibody to the housekeeping
gene GAPDH (data not shown). 
Effect of syncytialisation on mTOR and downstream signalling
components. Semi-quantitative RT-PCR analysis (comparing
gene expression with the housekeeping gene ß-actin) revealed
that in early stages of syncytialisation (50 μM forskolin for
48 h), the expression of mTOR and 4EBP was down-regulated
when compared with basal unstimulated cells. However, in
fully syncytialised cells (50 μM forskolin for 72 h) the gene
expression of mTOR and 4EBP was unaltered (Figs. 3 and 4).
mRNA expression of the isoforms S6K ·1 and ß2 was
unaffected by forskolin treatment at 48 and 72 h, whereas ·2
was down-regulated upon forskolin treatment (100 μM) at
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Figure 1. (A) Gene expression of mTOR, 4EBP and S6K isoforms. Lane 1,
DNA ladder; lane 2, cDNA from human placenta; lane 3, cDNA from BeWo
cells; lane 4, cDNA from JEG-3 cells; lane 5, negative control. (B) Immuno-
fluorescent analysis of mTOR in BeWo (I) and JEG-3 (II) cells.
Figure 2. (A) Expression of PCNA mRNA in treated and untreated BeWo
cells. Lane 1, DNA ladder; lane 2, cDNA from untreated BeWo cells (48 h);
lane 3, cDNA from stimulated BeWo cells (50 μM forskolin, 48 h); lane 4,
cDNA from untreated BeWo cells (48 h); lane 5, cDNA from stimulated
BeWo cells (100 μM forskolin, 48 h). (B) Protein expression of PCNA and
Pan-Cadherin. Lane 1, BeWo cells treated with 50 μM forskolin for 72 h;
lane 2, control, unstimulated BeWo cells (72 h), lane 3, BeWo cells treated with
100 μM forskolin for 72 h; lane 4, control, unstimulated BeWo cells (72 h).
Figure 3. Effect of forskolin at 48 h on gene expression of mTOR signalling
components. Lane 1, cDNA from stimulated BeWo cells (50 μM forskolin,
48 h); lane 2, cDNA from untreated BeWo cells (control); lane 3, cDNA from
stimulated BeWo cells (100 μM forskolin, 48 h); lane 4, cDNA from untreated
BeWo cells (control); lane 5, negative control.
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48 h (Figs. 3 and 4). Gene expression of ·2 and ß1 was also
altered at 72 h, with ·2 being down-regulated in fully
syncytialised cells (100 μM forskolin) treatment, whereas ß1
was up-regulated with forskolin treatment (Fig. 4).
The protein expression of mTOR was assessed in
syncytialised BeWo cells, using immunofluorescent analysis.
Similar intense cytoplasmic staining was detected in
unstimulated BeWo cells as previously described (Fig. 1B).
Although this approach is not quantitative, the expression of
mTOR at 48 and 72 h in both syncytialised and unstimulated
BeWo cells was very similar in terms of the intensity of the
immunostaining and the cellular localisation (Fig. 5).
The activity of p70S6K was assessed in stimulated
and unstimulated BeWo cells by measuring the effect of
forskolin on the phosphorylation status of S6K. Under basal
conditions (i.e. no forskolin treatment), there was no change
in the phosphorylation status of the p70S6K (Ser371,
Thr 389) when we compared treated and untreated BeWo
cells, and corrected over the housekeeping gene GAPDH at
48 or 72 h (Fig. 6).
Discussion
The two cell lines studied are widely used to investigate
placental physiology and function. These cell lines have distinct
fusigenic capacities. The JEG-3 cell line, despite being of a
choriocarcinoma origin, is unable to morphologically differen-
tiate and therefore it resembles the undifferentiated and hormo-
nally inactive cytotrophoblast cells, making it an appropriate in
vitro model to investigate first trimester placental events (16).
BeWo cells are fusigenic and when they are fully
differentiated (i.e. syncytialised) they resemble a third trimester
placental model. At this stage the predominant feature of the
human placenta is the hormonally active syncytiotrophoblast
layer. The multinucleated syncytiotrophoblasts cover the
external surface of the placental villous and are in direct inter-
face with maternal blood (17). Undifferentiated BeWo cells are
similar in morphology to primary trophoblast cultures, with a
monolayer and microvillar projections on the apical side. The
capability of BeWo cells to differentiate has established these
cells as an in vitro model to study immune, endocrine and
developmental aspects (18-20), as well as placental transport
mechanisms (21). In this report we demonstrate for first time
the expression of mTOR, p70S6K isoforms and 4EBP in these
two cell lines and provide evidence of how the process of
syncytialisation affects the expression of these components
as well as the activity of p70S6K. 
Immunofluorescent analysis revealed strong cytoplasmic
staining for mTOR in both cell lines. This is in agreement with
previous studies showing that mTOR is located chiefly in the
cytoplasm (8,14). 
MPARMPAKAS et al:  EXPRESSION OF mTOR IN HUMAN PLACENTAL CHORIOCARCINOMA68
Figure 4. Effect of forskolin at 72 h on gene expression of mTOR signalling
components. Lane 1, cDNA from stimulated BeWo cells (50 μM forskolin,
72 h); lane 2, cDNA from untreated BeWo cells (control); lane 3, cDNA
from stimulated BeWo cells (100 μM forskolin, 72 h); lane 4, cDNA from
untreated BeWo cells (control); lane 5, negative control.
Figure 5. Cellular distribution of mTOR in BeWo cells treated with forskolin
(Frk) at 48 and 72 h. 
Figure 6. Effect of forskolin (50 and 100 μM) at 48 and 72 h on Ser371 and
Thr389 phosphorylation of p70S6K. Lanes 1 and 4, control (unstimulated
BeWo cells); lanes 2 and 5, BeWo cells treated with 50 μM forskolin; lanes 3
and 6, BeWo cells treated with 100 μM forskolin.
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Previous studies show that mTOR also shuttles between
the nucleus and cytoplasm (22). The authors proposed that the
nucleo-cytoplasmic shuttling of mTOR is required for the
maximal activation of S6K1 (22). In our study, nuclear
expression of mTOR under basal conditions in JEG-3 and
undifferentiated BeWo was not observed. Even after forskolin-
induced syncytialisation, no apparent translocation of mTOR
was noted in BeWo cells at either 48 or 72 h. In relation to
human placenta, mTOR protein is highly expressed within the
cytosol of the syncytiotrophoblast (8). Future studies should
determine the cellular localisation of mTOR in human placentae
throughout pregnancy as well as in placentae from metabolically
complicated pregnancies.
In our experimental model, treatment with forskolin
induced a transient (48 h) decrease in the gene and protein
expression of mTOR in BeWo cells, as well as a decrease in
the gene expression of 4EBP. These results support a recent
study showing that forskolin altered the expression of
several genes during differentiation of BeWo cells. For
example, mRNA expression of SLPI, ELF-1·-1, prolyl
4-hydroxylase-ß and gastric associated differentially
expressed protein was up-regulated after forskolin induced
differentiation. In contrast, LMO-4 and Rab-5 interacting
protein transcripts were down-regulated during cytotro-
phoblast differentiation (18).
Interestingly, despite changes in the gene expression of the
p70S6K isoforms ·2 and ß1 at 72 h, the activity of this kinase
in terms of phosphorylation remains unaltered throughout. It
appears therefore that expression and phosphorylation of this
enzyme is differentially regulated in BeWo cells. Indeed, the
serine/threonine kinase p70S6K1 is also activated through
mTOR-insensitive signalling pathways. 
Microarray analysis demonstrated that a number of tran-
scripts were differentially expressed between BeWo and JEG-3
cells (23). These distinct characteristics suggest that each
cell line varies with regards to their ability to respond to
certain stimuli, such as hormones and nutrients. As a result,
downstream signalling cascades, including mTOR, might also
be differentially regulated. 
Collectively these novel data provide evidence that two
human choriocarcinoma cell lines express mTOR and its down-
stream signalling components, and syncytialisation events affect
gene expression of these components. In terms of using these
experimental models to study placental mTOR signalling, it
should be noted that there are differences in the expression of
genes between an immortalised choriocarcinoma cell line and
primary trophoblast cell cultures. Future studies, should map in
detail these components during the first, second and third tri-
mesters of pregnancy and expand observations in other critical
intrauterine tissues such as fetal membranes, as well in other
pathophysiological complications of pregnancy.
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